Group Executive Team

Dr. Behrenbruch is a co-founder of Telix and was appointed Managing Director and Group Chief Executive Officer on 3 January 2017. See above for further biographical details.

Mr. Smith has over 20 years’ experience in executive finance and general management across a broad range of industries, including in life-sciences, for publicly listed, private, international, and Australian government organizations. Prior to joining Telix, Darren was Global Chief Financial Officer and Company Secretary at Sirtex Medical Ltd (from June 2008 to March 2019).

Dr. Cade has over 20 years’ experience as an industry physician spanning the fields of novel biotechnology, pharmaceuticals and medical devices. Prior to joining Telix, David held senior executive roles at Cochlear Ltd, where he served as Chief Medical Officer, and at Sirtex Medical Ltd, where he served as Chief Medical Officer and in other senior roles across the US, Europe and Australia, gaining deep experience in the oncology, interventional radiology and nuclear medicine therapeutic areas.

Dr. Patti has over 20 years of experience in radiopharmaceutical and device manufacturing with particular expertise in network management and operations, including new radiopharmaceutical manufacturing, implementation and compliance.  Previously, as U.S. COO and GM for the Americas region, Darren led the successful U.S. and Canada launches of Illuccix® and ongoing market development for Telix in Brazil and the Latin America (LATAM) region. Prior to joining Telix, Darren held a variety of roles at Sofie Biosciences over a period of 15 years, most recently as Vice President of Operations where he led the operationalization of the Sofie-Lantheus PSMA-PET imaging program.

Ms. Moran-Adams has over 25 years’ experience driving proactive, results driven legal and compliance solutions worldwide, including more than 20 years’ experience in the pharmaceutical industry in various country, regional and global leadership roles. Prior to joining Telix, Lena was the Head of Legal and Business Conduct, Intercontinental at Gilead Sciences and a Global Head of Legal at Novartis. Lena is admitted to the bar and entitled to practice law in Australia, the UK and in New York.

Mr. Valeix leads the Company’s therapeutic pipeline commercialization and business development. He has more than 20 years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas. Previously, Richard worked at Advanced Accelerator Applications (AAA), a Novartis Company (from January 2014 to April 2021) where he served in the roles of General Manager for France, Switzerland, Belgium, Netherlands and Luxembourg, and Global Head of Marketing and Sales.

Mr. Richardson leads the development of the Company’s diagnostics, global marketing and commercial operations in the U.S. and Canada. He has more than 25 years’ experience in the healthcare industry, including seven years focused in sales, marketing and business operations in the radiopharmaceutical segment. Immediately prior to joining Telix, Kevin was the Chief Operating Officer of UroShape Medical, a technology company which has developed and successfully commercialized a medical device for a large, undertreated segment in the women’s health market. Prior to this, he spent seven years in the Americas division of Sirtex Medical Ltd.

Mr. Ortiz leads the “rest of world” commercial operations for Europe, Middle East and Africa (EMEA), Asia Pacific (APAC) and Latin America regions. He joined Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia. Prior to joining Telix, Raphaël worked at Advanced Accelerator Applications, a Novartis Company, and most recently in the role of Asia-Pacific Cluster Head, setting up the radioligand therapy operations in the region.

Mr. Stonecypher has over 25 years of experience in the life science industry in research, development, and commercialization of novel human medicines. An expert in Regulatory Affairs and Quality, James is passionate about rapidly advancing innovative therapies for high unmet needs and improving access to medicine. James has held senior leadership roles at major and emerging bio pharmaceutical companies in the US and Europe, including Amgen, Allergan, Micromet, and BioNTech.